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Objective: To identify whether cartilage master regulator SRY-related protein 9 (SOX9) mediates A dis-
integrin and metalloproteinase with thrombospondin motifs (ADAMTS) dysregulation during osteoar-
thritis (OA) cartilage degeneration.
Method: Twenty-two randomly selected OA patients were evaluated using Outerbridge Classiﬁcation via
arthroscopy. Haematoxylineeosin (HE), Safranin O and Masson staining were performed for the histo-
pathological assessment. The expression of ADAMTSs, collagen 2A1 (COL2A1), aggrecan (ACAN), cartilage
oligomeric matrix protein (COMP) and SOX9 were examined using real-time quantitative Polymerase
Chain Reaction (PCR) (RT-qPCR) and western blotting analysis. Immunohistochemistry (IHC) analysis was
performed to investigate the production of ADAMTSs in cartilage tissues. The association between SOX9
production and ADAMTSs, COL2A1, ACAN, and COMP expression was established by full-depth cartilage
biopsies.
Results: ADAMTSs expression levels were repressed at stage 1, while a signiﬁcant increase was observed
at the progressive stage of OA. SOX9 was upregulated at stage 1 and suppressed at a later stage of
cartilage development, particularly in cartilage with severe damage. In addition, SOX9 repressed the
expression of ADAMTSs and promoted COL2A1, ACAN and COMP expression in human chondrocytes.
SOX9 was recruited to the promoters of ADAMTS-4 and ADAMTS-7. SOX9 expression was negatively
correlated with ADAMTSs production and was positively associated with COL2A1, ACAN and COMP
expression. Inhibition of ADAMTSs markedly increased the production of COL2A1, ACAN and COMP in
chondrocytes isolated from the early stage of OA.
Conclusions: These ﬁndings indicated that SOX9 upregulation might mediate ADAMTSs suppression at
the early stage of human OA. In addition, SOX9 could be used as a potential therapeutic agent for human
OA at an early stage.
© 2015 The Authors. Published by Elsevier Ltd and Osteoarthritis Research Society International. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).o: Y. Wang, Department of
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Osteoarthritis (OA) is a chronic and complex multifactorial joint
disease that is characterized by the progressive degradation of
articular cartilage and joint inﬂammation1e3. The extracellular
matrix (ECM), a network of proteins and macromolecules, provides
both strength and nutrients for chondrocytes. The destruction of
ECM components, such as the proteoglycan aggrecan (ACAN),
cartilage oligomeric matrix protein (COMP) and type II collagen,
usually induce OA4,5. These processes involve the coordinatedociety International. This is an open access article under the CC BY-NC-ND license
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However, the underlying pathophysiological process of the early
stage of OA has not been completely elucidated.
A disintegrin and metalloproteinase with thrombospondin mo-
tifs (ADAMTS) family and matrix metalloproteinase (MMP) play an
important role in OA pathogenesis7e9 by degradingmatrix and non-
matrix substrates and by shifting the balance from the anabolic
toward the catabolic state with gradual progressive cartilage loss.
Limited studies have shown that ADAMTSs can degrade the ECM
and are highly expressed in OA cartilage. ADAMTS-4 and ADAMTS-5
have been reported to be crucial for degrading the matrix10.
ADAMTS-7 forms a positive feedback loop with tumour necrosis
factor (TNF)-a in the pathogenesis of OA11. ADAMTS-12 contributes
to the progressive loss of cartilage and joint dysfunction12. However,
the molecular mechanisms underlying the activity of ADAMTSs at
the early stage of OA are poorly characterized.
SRY-related protein 9 (SOX9) is an essential transcription factor
regulating the expression of many ECM genes, such as ACAN and
collagen type II13e15. Haploinsufﬁciency of SOX9 can induce cam-
pomelic dysplasia, which is a severe syndrome caused by inade-
quate cartilage formation during development, underlying its
importance to the chondrocyte phenotype16,17. Nevertheless, little
is known regarding SOX9 expression at the early stage of OA as well
as with regard to the relationship between SOX9 and ADAMTSs
during cartilage degeneration in human OA pathogenesis.
In this study, we found that SOX9 upregulation mediated the
suppression of ADAMTSs at the early stage. Furthermore, knock-
down of SOX9 signiﬁcantly enhanced ADAMTS-4, ADAMTS-5,a
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Fig. 1. Extraction and stage of the OA tissue. The grades of articular cartilage were classiﬁed u
points, located in the medial tibial plateau (M) or lateral tibial plateau (L), were recorded fro
cartilage of this position was classiﬁed as Grade II, and this position was recorded as (M:X
markers in the medial tibial plateau (A). Cartilage was obtained from the tibial plateau by
arthroscopic observation (B). H&E staining (upper panel), Safranin O/Fast green staining (
samples and OA samples (C). Scale bar, 50 mm. The sections shown are representative of OADAMTS-7 and ADAMTS-12 production and downregulated
collagen 2A1 (COL2A1), ACAN and COMP expression in human
chondrocytes, indicating that SOX9 may play an important role in
cartilage protection. Taken together, these ﬁndings comprehen-
sively elucidate their properties at different stages of OA and open
new possibilities for new therapeutic strategies against OA.
Methods
Reagents
Antibodies against ADAMTS-5 (A6727) were obtained from Sig-
maeAldrich (St. Louis, MO, USA). Antibodies against ADAMTS-4 (sc-
25582), ADAMTS-7 ADAMTS-12 (sc-25583), COL2A1 (sc-28887),
ACAN (sc-25674), b-actin (sc-47778) and SOX9 (sc-20095) were
purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA).
Antibodies against COMP (ab128893) were obtained from Abcam
(Cambridge, MA, USA). Antibodies against ADAMTS-7 (HPA034581)
were obtained from Atlas antibodies AB (St. Louis, MO, USA).
Specimen collection and patients
Human articular cartilage specimens were obtained from knee
joints at the time of total knee replacement surgery from patients
[n ¼ 22, mean ± 95% conﬁdence intervals (CIs), age: 55.7 years
(52.8e56.9), 54.5% men] graded using an arthroscopic diagnosis.
Relatively normal cartilage evaluated as stage 0 was regarded as the
control group. Tissues used as controls were already signiﬁcantlyb
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3Y2, II), which was the most posterior and the second medial point among the three
drilling holes of the same diameter (4.5 mm) with the reference point marked using
middle panel), and Masson staining (lower panel) of articular cartilage from control
A tissue from one patient.
Table I
Primers used for RT-qPCR
Gene
(Genebank accession number)
Sequence
ADAMTS-4 50-GGCCACCGGAGCATCTACTTGGCC-30 (S)
(NM_005099.4) 50-GGCTGCAGTGGCCCCGCTGTAGC-30 (AS)
ADAMTS-5 50-GAACTATAGCGGTTGGAGCCACAG-30 (S)
(NM_007038.3) 50-GCTGCCATGACTAGTGACAGAG-30 (AS)
ADAMTS-7 50-GACAGGGCTGCCCGAGGAAGACAG-30 (S)
(NM_014272.3) 50-CAGCGTCTCGCAGAACCCGAAGG-30 (AS)
ADAMTS-12 50-GAAGACCAAGACCAATGTCTATG-30 (S)
(NM_030955.2) 50-GTCTGGCAGAAACTGGCTGACAG-30 (AS)
Col2A1 50-GCCTCGCGGTGAGCCATGATC-30 (S)
(NM_001844.4) 50-CTCCATCTCTGCCACGGGGT-30 (AS)
ACAN 50-TAGAGGATGTGAGTGGTCTT-30 (S)
(NM_001135.3) 50-TCCACTAAGGTACTGTCCAC-30 (AS)
COMP 50-AACACGGTCACGGATGACGACTATG-30 (S)
(NM_000095.2) 50-CACAGAGCGTTCCGCAGCTGTTC-30 (AS)
SOX9 50-GAGCTGAGCAGCGACGTCATCT-30 (S)
(NM_000346.3) 50-GGCGGCGCCTGCTGCTTGGACA-30 (AS)
b-actin 50-ATCACCATTGGCAATGAGCG-30 (S)
(NM_001101.3) 50-TTGAAGGTAGTTTCGTGGAT-30 (AS)
S sense, AS antisence.
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healthy control. All of tissue samples were obtained from joints
affected by OA and the areas of each individual patient's articular
cartilage were selected and graded as stage 0e4 according to the
Outerbridge Classiﬁcation scheme. Cartilage specimens that
included all of the cartilage layers and subchondral bone were
separately harvested by drilling holes (4.5 mm) [Fig. 1 (B)], the lo-
cations of which were determined under arthroscopy [Fig. 1(A)].
The present study was reviewed and approved by the institutional
ethics review board (No. 20090611-3) of the General Hospital of
People's Liberation Army (Beijing, China). Written informed con-
sent was obtained from each patient.
Cell culture
Human chondrocytes were isolated from autopsy donors that
were graded macroscopically according to a modiﬁed Outerbridge
scale. Only normal (Grade 0: normal and intact cartilage) or severe
OA (Grade III: maximal ﬁbrillation) cartilage was used for the
studies. Chondrocytes were incubated in Dulbecco's modiﬁed Ea-
gle's (DMEM) high glucose medium containing 10% foetal calf
serum (FCS), 100 IU/mL penicillin and 100 mg/ml streptomycin at
37C in an atmosphere of 5% CO2. First-passage chondrocytes at 85%
conﬂuence were used for all experiments.
Transfection
To construct the pXJ40-myc-tagged human Sox9, Sox9 cDNA
was ampliﬁed using two primer sets (Forward 50-CGGGATCCAT-
GAATCTCCTGGACCCCTTCA-30 and Reverse 50-CCGCTCGAGT-
CAAGGTCGAGTGAGCTGTGTG-30) that contained BamHI and XhoI
restriction-enzyme sites. The PCR products were digested with
BamHI and XhoI and cloned into the pXJ40-myc vector. Human
chondrocytes were seeded at a density of 4  104 in 12- or 24-well
plates. On the following day, cells were transfected with Sox9 using
Lipofectamine 2000 (Invitrogen, CA, USA), according to the man-
ufacturer's instructions: 1 day before transfection, the cells were
plated in growth medium without antibiotics such that the cells
were 80% conﬂuent at the time of transfection. The optimal ratio of
DNA/Lipofectamine 2000 in our systemwas 1:1.5. The solutionwas
mixed gently and incubated for 20 min at room temperature, and
the DNA/Lipofectamine 2000 complexes were then added to each
well. After 4e6 h, the culture medium was changed. Cell lysates
were collected for different types of experiments after 48 h of
transfection. To monitor the transfection efﬁciency, the pEGFP-C1
plasmid (Clontech Laboratories, CA, USA) was transfected each
time in a parallel well.
Total RNA extraction, reverse transcription and real-time
quantitative PCR (RT-qPCR)
Total RNA from tissues or cultured chondrocyte samples con-
taining miRNA was extracted and reverse-transcribed to cDNA us-
ing the RNeasyMini kit (Qiagen, Valencia, CA, USA) according to the
manufacturer's protocol. Total RNA (2 mg) was reverse-transcribed
in a total volume of 25 mL containing RT buffer (Takara), 200 U of
Moloney murine leukemia virus Reverse Transcriptase (M-MLV RT)
(Takara), 20 U of RNasin (Takara), and 0.2 mg of a random primer
(Takara). The reaction was performed at 42C for 60 min and 95C
for 10 min cDNA was stored at 20C until further use. RT-
qPCR reactions were performed using the SYBR Premix Ex Taq
Master Mix (2) (Takara, Japan) as previously described. The rela-
tive quantiﬁcation value of the target, normalized to the control,
was calculated using the comparative Ct method. The primers used
for RT-qPCR analysis are shown in Table I.Western blotting analysis
Proteins were extracted from tissues or chondrocytes using RIPA
buffer (50 mM TriseHCl (pH 7.4), 150 mM NaCl, 20 mM EDTA, 1%
Triton X-100, 1% sodium deoxycholate, 1% SDS and protease in-
hibitors,WheatonScience) on ice for 30min andanalysed using SDS-
PAGE electrophoresis. Membranes were subsequently incubated
with primary antibodies against b-actin (Santa Cruz, 1:500 dilution),
ADAMTS-4 (Santa Cruz, 1:100 dilution), ADAMTS-5 (Sigma, 1:100
dilution), ADAMTS-7 (Atlas antibodies, 1:200 dilution), ADAMTS-12
(Santa Cruz, 1:100 dilution), SOX9 (Santa Cruz, 1:500 dilution),
COL2A1 (Santa Cruz, 1:50 dilution) and ACAN (Santa Cruz, 1:50
dilution) overnight at 4C, followed by incubationwith a horseradish
peroxidase conjugate. The immunocomplexes were visualized by
chemiluminescence using an ECL kit (Amersham Biosciences).
Small interfering RNA (siRNA)
pLenti-H1 vector-containing siRNA constructs for ADAMTS-4,
ADAMTS-5, ADAMTS-7, ADAMTS-12 and SOX9 were generated
using recombinant PCR. The empty vector was treated as the
control. The sequences of siRNAs were as follows: ADAMTS-4: 50-
AAGCATCCGCAATCCTGTCAG-30; ADAMTS-5: 50-AAGA-
TAAGCGCTTAATGTCTT -30; ADAMTS-7: 50-ACCTAA AGATCACG-
CACCA-30; ADAMTS-12: 50-ACACATCACACACACCCAA-30; SOX9:
50-CAGCGAACGCACATCAAGA-30. To produce the lentivirus,
HEK293T cells were co-transfected with recombinant lentiviral
vectors (pLenti-H1/ADAMTS-4, pLenti-H1/ADAMTS-5, pLenti-H1/
ADAMTS-7, pLenti-H1/ADAMTS-12 and pLenti-H1/SOX9) and
pPACK Packaging Plasmid Mix (System Biosciences) using the
Megatran reagent (Origene) as previously described28. To infect
human chondrocytes, lentiviruses were collected after 48 h of
transfection and added to the medium of target cells with 8 mg/
ml polybrene (SigmaeAldrich). Chondrocytes were harvested for
measurement after 72 h of transfection.
Chromatin immunoprecipitation (ChIP)
A ChIP assay was performed using a commercially available kit
(Millipore, MA, USA) according to the manufacturer's in-
structions29. Brieﬂy, chondrocytes isolated from autopsy donors
were cross-linked in 3.7% formaldehyde, pelleted, and resuspended
in lysis buffer. Cells were sonicated, followed by centrifugation to
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Pellet Protein G magnetic beads were added to the sample and
incubated for 1 h at 4C with antibodies against SOX9. Chromatin
was collected, puriﬁed, and de-crosslinked at 62C for 2 h and then
at 95C for 10min. The precipitated DNA fragments were quantiﬁed
using RT-qPCR analysis. ChIP analysis was performed using the
“Fold Enrichment Method”, which was also called “relative to the
no-antibody control”. Using this method, the ChIP signals were
represented as the fold increase in signal of SOX9 relative to the IgG
signal. The primers used for the ChIP assay are displayed in Table II.
Histopathological assessment
Cartilage samples were ﬁxed in 4% buffered paraformaldehyde
for 48 h and then decalciﬁed with buffered Ethylene Diamine Tet-
raacetic Acid (EDTA) (20% EDTA, pH 7.4). The tissues were then
embedded in parafﬁn, sectioned and stained with haematox-
ylineeosin (HE), Safranin O/Fast green andMasson's trichrome. The
histopathological changes were scored using the modiﬁed Mankin
grading system in a blind manner18.
Immunohistochemistry (IHC)
Articular cartilage sections were pretreated for 10 min with
trypsin (0.05%) before treatment with 3% (vol/vol) H2O2 for 15 min.
The sections were then blocked with 10% goat serum for 1 h at
room temperature. After washing with Phosphate Buffered Saline
(PBS), antibodies against ADAMTS-4 (sc-25582, Santa Cruz, 1:25
dilution), ADAMTS-5 (A6727, Sigma, 1:50 dilution), ADAMTS-7
(HPA034581, Atlas antibodies, 1:50 dilution) and ADAMTS-12 (sc-
25583, Santa Cruz, 1:50 dilution) were applied to the sections and
incubated for 1 h at room temperature. The sections were then
washed with PBS and incubated for 15 min with a biotinylated
secondary antibody using a Histostain Plus kit (Invitrogen, Carls-
bad, CA, USA). The sections were washed and incubated for 2 min
with 3, 30-diaminobenzidine (DAB) substrate. Using light micro-
scopy, all of the IHC staining was assessed by two pathologists who
were blind to the origin of the specimen. The German semi-
quantitative scoring system is widely accepted with consideration
of the staining intensity and extent of the area used30, where 0 in-
dicates no staining; 1 indicates weak staining; 2 indicates moderate
staining; and 3 indicates strong staining. In addition, the percent-
age of staining was given a score of 0 (<5%), 1 (5e25%), 2 (25e50%),
3 (51e75%), or 4 (>75%). These two scores were multiplied,
resulting in the ﬁnal score. For ADAMTS-4, ADAMTS-5, ADAMTS-7
and ADAMTS-12, we deﬁned a score of 0 as negative and a score
of 1e12 as positive.
Statistical analysis
The data were expressed as the mean ± 95% CIs. Statistical anal-
ysis was performed using KruskaleWallis test for multiple compar-
ison, and P < 0.05 was indicated statistical signiﬁcance. The
ManneWhitney U test or Wilcoxon signed-rank test was used to
account for multiple testing. All experiments were performed using
samples obtained from at least three different donors with duplicate
or triplicate replication as indicated in the ﬁgure legends. EvaluationTable II
Primers sequences for ChIP
Name Forward (50 / 30)
ADAMTS-4 promoter CTCCTTCCTGGGGAT
ADAMTS-4 upstream ACCCTTTGTCCGACTC
ADAMTS-7 promoter AATGAAAGGGCCCAG
ADAMTS-7 upstream AGCAAGACCAGCTGGof the RT-qPCR data was performed using one-way ANOVA with
Tukey's post hoc test. Analysis of the statistical correlation between
the expression of SOX9, ADAMTS-4, ADAMTS-5, ADAMTS-7,
ADAMTS-12, COL2A1, ACAN and COMP was performed with tissues
that were freshly isolated from 22 OA patients using Spearman rank
analysis with GraphPad PRISM 6 (GraphPad, San Diego, CA, USA).
Results
Identiﬁcation of different stages of OA using histopathological
staining
We primarily investigated the different stages of cartilage tis-
sues. Human articular cartilage specimens were obtained from
knee joints at the time of total knee replacement surgery from
patients who were graded using an arthroscopic diagnosis. Knee
cartilage was obtained by drilling holes [Fig. 1(B)], the locations of
which were determined using arthroscopy [Fig. 1(A)]. The stages of
OA were diagnosed using H&E, Safranin O/Fast green, and Masson
staining [Fig. 1(C)].
Expression of ADAMTSs at the early stage of OA
To identify the different expression of the ADAMTSs in the
control sample (stage 0) and early stage OA (stage 1) cartilage, we
ﬁrst evaluated the mRNA levels of ADAMTS-4, ADAMTS-5,
ADAMTS-7 and ADAMTS-12 using RT-qPCR. We found that the
mRNA levels of ADAMTS-4 and ADAMTS-5 [Fig. 2 (A and B)] as well
as ADAMTS-7 and ADAMTS-12 [Fig. 2(C and D)] could be detected
in both the control and OA human articular cartilage. Interestingly,
the transcriptional levels of the ADAMTSs were signiﬁcantly
repressed in stage 1 compared with the control sample group
[Fig. 2(AeD)].
To further assess the potential involvement of ADAMTS-4,
ADAMTS-5, ADAMTS-7 and ADAMTS-12 in the early OA process,
we performed IHC and western blotting analysis to analyse
whether this trend also occurred at the protein level. Western
blotting analysis conﬁrmed that the expression of ADAMTS-4 and
ADAMTS-5 [Fig. 3 (A and B)] as well as ADAMTS-7 and ADAMTS-12
[Fig. 3(C and D)] was remarkably decreased at the early stage of OA
(stage 0 vs stage 1). IHC staining demonstrated that ADAMTS-4-,
ADAMTS-5-, ADAMTS-7- and ADAMTS-12-positive chondrocytes
were observedmainly in the superﬁcial layers of the control sample
and OA human articular cartilage and that ADAMTS-4, ADAMTS-5,
ADAMTS-7 and ADAMTS-12 were mainly present in the cytoplasm
[Fig. 3(E)]. Similarly, the expression of ADAMTSs was also sup-
pressed at stage 1 (P < 0.01) [Fig. 4 ], which was consistent with the
mRNA expression levels of ADAMTSs at stage 1.
Expression of ADAMTSs at the later stage of OA
Next, we examined themRNA expression of ADAMTSs at the later
stage of OA. RT-qPCR analysis suggested that the mRNA levels of
ADAMTS-4, ADAMTS-5, ADAMTS-7 and ADAMTS-12 at the later
stage of OA cartilage (stage 2 to stage 4)were upregulated in contrast
to stage 1 [Fig. 2(AeD)]. In addition, the expression of ADAMTSs was
gradually enhanced from stage 2. Consistent with the mRNA levels,Reverse (50 / 30)
TTCCTG GTAGGGGCAATTTCTGCTCA
CTCTA ACTTGCCTGACCCTGGTTCT
GAGATT TGTGCCCCCTGCCCTCTGAG
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Fig. 2. Analysis of the mRNA levels of ADAMTSs at different stages of OA. Total RNA from the cartilage of 22 patients were extracted and transcribed into cDNA. The mRNA
expression of ADAMTS-4 (A), ADAMTS-5 (B), ADAMTS-7 (C) and ADAMTS-12 (D) in cartilages obtained, from stage 0 to stage 4. The mRNA levels were analysed using RT-qPCR and
normalized using b-actin. Bars indicate the mean ± 95% CI of triplicate experiments from each sample obtained from 22 patients. *P < 0.05; **P < 0.01.
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also showed similar trends [Fig. 3]. This sustainable increase in the
mRNA and protein levels of the ADAMTSswas signiﬁcantly observed
in OA cartilage compared with control cartilage.
Expression of SOX9 and ECM components at different stages of OA
To examine the effects of the ADAMTSs on the ECM components,
we identiﬁed the expression of SOX9 and the proteoglycans COMP
and COL2A1 at different stages of OA using RT-qPCR [Fig. 4(A)] and
western blotting analysis [Fig. 4(B)]. Expectedly, the production of
COL2A1, ACAN, COMP and SOX9 demonstrated a transient upre-
gulation at stage 1 compared with control cartilage and subse-
quently decreased gradually at the later stage of OA, indicating an
inverse trend compared to the ADAMTSs.
Associations between SOX9, ADAMTSs, COL2A1, ACAN and COMP at
the early stage of OA
The potential pathophysiological of SOX9 in early stage (stage 1)
OA cartilage was investigated by examining the relationship be-
tween SOX9 and the anabolic factors ACAN and COMP as well as
between SOX9 and ADAMTS-4, ADAMTS-5, ADAMTS-7, and
ADAMTS-12. An association analysis indicated a remarkable posi-
tive correlation between SOX9mRNA expression levels and those of
COL2A1 [Fig. 4(C)], ACAN [Fig. 4(D)] and COMP [Fig. 4(E)]. In
contrast, the expression of SOX9 was inversely correlated with
ADAMTS-4 [Fig. 4(F)], ADAMTS-5 [Fig. 4(G)], ADAMTS-7 [Fig. 4(H)],
and ADAMTS-12 [Fig. 4(I)].
Effects of SOX9 on ADAMTSs, COL2A1, ACAN and COMP in human
chondrocytes
To identify whether the associations previously found in freshly
isolated tissues obtained from patients were correlated, we next
studied whether SOX9 could modulate catabolic activity in chon-
drocytes isolated from stage 1 cartilage samples. RT-qPCR andwestern blotting analysis of supernatant cultures suggested that
SOX9 overexpression repressed ADAMT-4, ADAMTS-5, ADAMTS-7
and ADAMTS-12 expression, while knockdown of SOX9 increased
ADAMTS-4, ADAMTS-5, ADAMTS-7 and ADAMTS-12 activity
(P<0.05). In addition, the expressionofADAMTSswas inhibited after
SOX9 rescue in SOX9 knockdown chondrocytes [Fig. 5 (A)]. In addi-
tion, SOX9 promoted the expression of cartilage matrix genes, such
as COL2A1, ACAN and COMP, and the inhibition of SOX9 signiﬁcantly
suppressed the expression of COL2A1, ACAN and COMP [Fig. 5(B)],
suggesting that SOX9 induced the composition of human cartilage
ECM components and antagonized the progression of OA. Taken
together, these ﬁndings indicated a crucial role of SOX9 in cartilage
protection that is potentially correlated with cartilage homeostasis.Inhibition of ADAMTSs increased the expression of cartilage matrix
genes at an early stage of OA
Among the ECM components, COL2A1, ACAN and COMP are
regarded as important biomarkers of cartilage, which determines
the levels of OA degeneration. To further study whether the upre-
gulation of cartilage genes at the early stage of OA was caused by
ADAMTSs, human chondrocytes isolated from human knee carti-
lage at stage 1 were independently transfected with siRNAs for
ADAMTS-4, ADAMTS-5, ADAMTS-7 and ADAMTS-12. Alternations
in the mRNA and protein levels of COL2A1, ACAN and COMP were
evaluated using RT-qPCR and western blotting analysis. Our data
suggested that the production of COL2A1, ACAN and COMP were
upregulated when ADAMTSs were knocked down [Fig. 5(DeG)],
indicating that the knockdown of ADAMTSs stimulated cartilage
matrix gene expression at the early stage of OA. To further conﬁrm
the direct regulation of ADAMTS by SOX9, we performed a
ChIP assay. These results indicated that SOX9 could be recruited to
the promoters of ADAMTS-4 and ADAMTS-7, but not to a region
that was approximately 2-kb upstream of the ADAMTS-4 and
ADAMTS-7 promoters [Fig. 5(HeI)]. Taken together, these data
strongly suggested that SOX9 inhibits the transcription of ADAMTSs
via regulated recruitment of SOX9 to the ADAMTS promoter.
Fig. 3. Analysis of the protein levels of ADAMTSs at different stages of OA. Expression levels of ADAMTS-4 (A), ADAMTS-5 (B), ADAMTS-7 (C), and ADAMTS-12 (D) in human cartilage
of different stages using RT-qPCR and western blotting analyses. The different stages were identiﬁed using the Outerbridge Classiﬁcation. Box-and-whisker plots below the
immunoblotting images showed the average expression of ADAMTS. The expression of ADAMTS at different stages of OAwas plotted and compared (ManneWhitney U test). In box-
and-whisker plots, the horizontal bars indicate the medians, the boxes indicate the twenty ﬁfth to seventy ﬁfth percentiles, and the whiskers indicate the tenth and ninetieth
percentiles. *P < 0.05 vs stage 0; *P < 0.01 vs stage 0. Immunohistochemical analysis of ADAMTSs at different stages of OA. ADAMTS-4 (aee) ADAMTS-5 (fej), ADAMTS-7 (keo) and
ADAMTS-12 (pet) protein levels at different stages of OA were detected using IHC on sections of parafﬁn-embedded pallets. Images were obtained using a 200 objective (E). Scale
bar, 50 mm. Sections shown are representative of OA tissue from one patient. Western blots are representative of experiments from six different patients with similar results.
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ADAMTSs consist of a family of 19 secreted enzymes that have
been implicated in numerous physiological processes, such as
development, invasion, angiogenesis and coagulation19,20.Abnormal expression of ADAMTS family members has been iden-
tiﬁed in the pathogenesis of various types of diseases, including OA.
ADAMTS-7 and ADAMTS-12 are important in the degradation of
COMP, and collagen type II is important in the progression of
arthritis12,21; the levels of ADAMTS-7 and ADAMTS-12 are
Fig. 4. Correlation analysis between SOX9 and COL2A1, ACAN, and COMP in human OA cartilage samples. The expression of COL2A1, ACAN, COMP and SOX9 in human cartilages at
different stages (A, B). mRNA expression was identiﬁed using RT-qPCR. The protein proﬁles were examined using western blotting analyses. Data obtained from stage 0 was treated
as the control group. Data were shown as the mean ± 95% CIs. *P < 0.05; **P < 0.01. (CeH) Correlations between the expression levels of SOX9 and COL2A1(C), ACAN (D), COMP (E),
ADAMTS-4 (F), ADAMTS-5 (G), ADAMTS-7 (H) and ADAMTS-12 (I) (P < 0.01) in human cartilage at stage 1. COL2A1, ACAN, COMP and SOX9 relative mRNA expression levels at stage 1
were examined using RT-qPCR. The scores of ADAMTS-4, ADAMTS-5, ADAMTS-7 and ADAMTS-12 at stage 1 of OA were identiﬁed using immunohistochemical analysis.
Q. Zhang et al. / Osteoarthritis and Cartilage 23 (2015) 2259e2268 2265signiﬁcantly elevated in the cartilage and synovium of patients with
arthritis. ADAMTS-4 and ADAMTS-5 are also considered to be key
ECM degradation aggrecanases underlying OA22,23. Although
several reports have studied the mechanisms of ECM degradation,
inﬂammation and other factors involved in the OA process, our
understanding of OA degeneration and the precise mechanism of
ADAMTS-mediated degeneration at the early stage of OA have not
been fully elucidated. Thus, we investigated the expression of
ADAMTSs at the early stage of OA using arthroscopic classiﬁcation
and found that they were downregulated at the early stage, butdemonstrated a sustainable increase in the later stage of OA, which
simultaneously demonstrates their importance during the course
of human cartilage ECM degradation.
ADAMTSs are known to be involved in the degradation of ECM
components, such as ACAN, COMP and COL2A1, as well as other
factors. In our study, we found that knockdown of these enzymes
not only affected the protein levels of ECM components but also
affected their mRNA levels, which indicated that ADAMTSs plays a
dual role in controlling the levels of ECM components. With the
exception of their classical enzyme activities to degrade substrates,
Fig. 5. SOX9 repressed ADAMTSs expression levels in human chondrocytes. Human chondrocytes were transfected with control siRNA, SOX9 siRNA, empty vector or the SOX9
plasmid construct (A, B). SOX9 was also rescued in SOX9 knockdown chondrocytes after 48 h of transfection. The mRNA expression levels of ADAMTS-4, ADAMTS-5, ADAMTS-7, and
ADAMTS-12 (A) and COL2A1, ACAN, and COMP (B) in human chondrocytes after 72 h of transfection using RT-qPCR. The protein proﬁles of ADAMTS-4, ADAMTS-5, ADAMTS-7, and
ADAMTS-12 (A) and COL2A1, ACAN, and COMP (B) in human chondrocytes were identiﬁed using western blotting analyses. Data are shown as the mean ± 95% CIs. *P < 0.05;
**P < 0.01. (C) Bright ﬁeld (top), ﬂuorescence (middle) and merged (bottom) microscopy of human chondrocytes 96 h following transfection with vector labelled with Green
Fluorescent Protein (GFP). (DeG) Human chondrocytes were transfected with siRNAs for ADAMTS-4, ADAMTS-5, ADAMTS-7 or ADAMTS-12. Control siRNA was treated as the
control. The mRNA and protein levels of COL2A1, ACAN and COMP obtained from chondrocytes after 72 h of transfection were measured using quantitative RT-PCR and western
blotting analysis. RT-PCR and western blots are representative of experiments from three different patients with similar results (n ¼ 3). (HeI) ChIP assay for SOX9 occupancy on the
ADAMTS-4 promoter (H), ADAMTS-7 promoter (I) or upstream of the promoter in human OA chondrocytes (passage 1). Data are shown as the mean ± 95% CIs. *P < 0.05; **P < 0.01.
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the expression of transcriptional factors (TFs) or by changing the
recruitment of TFs to the promoters of the substrates. However,
which transcription factors participate in this process requires
further investigated.
Importantly, SOX9 is essential for the ability of chondrocytes to
produce cartilage matrix13. Fukui N et al. revealed that the mRNA
expression of SOX9 tended to be reduced in the degenerated areas,
particularly in the upper region of the degenerated cartilage in OA
cartilage. Within OA cartilage, the expression of cartilage matrix
genes was signiﬁcantly correlated with SOX9 expression24.
Considering the importance of SOX9 in the development and
maintenance of the chondrocyte phenotype, its reduction in OA
may contribute to cartilage pathology. To investigate the potential
mechanism underlying the decreased expression of ADAMTS-4,
ADAMTS-5, ADAMTS-7 and ADAMTS-12 in stage 1 of OA and to
assess the potential role of SOX9 in OA pathogenesis, we deter-
mined the expression of SOX9 at different stages of OA and found
that SOX9 was upregulated in the early stage of OA, but was
downregulated in the later stage of OA. Inhibition of SOX9 mark-
edly suppressed COL2A1, COMP, and ACAN production, but
increased the expression of ADAMTS-4, ADAMTS-5, ADAMTS-7 and
ADAMTS-12, indicating the important function of SOX9 in cartilage
equilibrium between matrix deposition and degradation, suggest-
ing that stage 1 may be a generation period of OA [Fig. 6 ]. However,
cartilage has a limited repair and regeneration capacity, and thus,
cartilage damage often results in dysfunction and OA pathogenesis,
suggesting that stage 2 to stage 4 is the lost generation period.
The transcription factor SOX9 plays an essential role in regula-
tion of chondrocyte development. It is known that both SOX9
directly upregulates the gene expression of ECM components,
including COL2A1, COMP and ACAN, while ADAMTSs downregulate
them. However, the relationship between SOX9 and ADAMTSs is
largely unknown. A research group examined the expression
pattern and levels of Sox9 in ADAMTS-5 null mice. They observed
an increase in Sox9 expression in ADAMTS-5/ valve mesen-
chyme, although the mechanism is undeﬁned25. In our previous
study, we found that ADAMTS-7 and ADAMTS-12 could down-
regulate the expression of SOX9 in endplate cells26. Taken together,
these ﬁndings indicated that ADAMTS could regulate SOX9. How-
ever, there are some clues as to whether SOX9 regulates ADAMTSsFig. 6. A schema depicting the hypothesized regulatory mechanism of SOX9 in the express
interleukin-1 beta (IL-1b), repress SOX9 expression and activate the expression of ADAMTSs
the promoters of ADAMTSs, thereby enhancing the expression of ADAMTSs at the early sta
Thus, SOX9 can be regarded to be a repressor of ADAMTSs and a protector of the early stage
ECM marker downregulation.or vice versa. Meelis Kadaja et al. used RNA sequencing (RNA-seq) to
identify SOX9-dependent transcriptional changes and ChIP and
deep sequencing (ChIP-seq) to identify SOX9-bound genes in hair
follicles (HF-SCs) and found a large cohort of ECM remodelling
factors, including ADAMTS-10, ADAMTS-14, and ADAMTS-1, which
were upregulated in SOX9 KO cells. This ﬁnding indicated that SOX9
could directly downregulate ADAMTS27. In our study, we usedmore
direct methods by performing both SOX9 overexpression and
knockdown experiments to determine both the mRNA and protein
expression levels of ADAMT-4, ADAMTS-5, ADAMTS-7 and
ADAMTS-12 and found that overexpression of SOX9 suppressed the
activity of the ADAMTSs, while knockdown of SOX9 increased the
activity of the ADAMTSs. Expression of ADAMTS was inhibited after
SOX9 rescue in SOX9 knockdown chondrocytes. On the basis of the
RNA and CHIP-Seq analysis, we hypothesized that SOX9 directly
binds to the promoters of ADAMTSs and affects their transcription.
Thus, we performed a ChIP assay and conﬁrmed that SOX9 was
recruited to the promoters of ADAMTS-4 and ADAMTS-7. These
data collectively indicated that SOX9 could negatively and directly
regulate the transcription of ADAMTSs. Our ﬁnding that ADAMTSs
may represent a novel target of SOX9 is consistent with previous
ﬁndings.
We observed that the transfection efﬁciency of myc-SOX9 was
approximately 40%. As a result, the mRNA levels of the entire
populationmight be expected to be 40% lower. However, in the case
of ADAMTS-7, these levels were reduced to 20e30% of the controls.
This ﬁnding might be due to experimental variability, an indirect
effect of SOX9 involving communication between transfected and
non-transfected cells, or a preferential transfection of a subpopu-
lation of cells that are higher producers of ADAMTS-7.
In conclusion, SOX9 upregulation mediates the repression of
ADAMTSs at the early stage of OA. In addition, SOX9 expression
was negatively correlated with the production of ADAMTSs, sug-
gesting that SOX9 could function as a protective regulator in hu-
man articular cartilage. However, further investigation accounting
for the dysregulation of SOX9 and ADAMTSs at the early stage of
OA requires further studies. Thus, the identiﬁcation of the mech-
anisms underlying this process may highlight the development of
a therapeutic target for OA, which could provide an alternative
treatment strategy for this disease that is distinct from surgical
intervention.ion of ADAMTSs at stage 1 of human OA. Inﬂammatory cytokines, such as TNF-a and
. In addition, inﬂammatory cytokines inhibit the recruitment of the repressor SOX9 to
ge of human OA, and resulting in an increase in COL2A1, ACAN and COMP expression.
of OA, either by directly regulating ECM markers or by suppressing ADAMTS-mediated
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